First-line treatment of patients with sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to anti-angiogenic targeted therapy, […]

read more

Atexolizumab plus bevacizumab for sarcomatoid kidney cancer

A study published in European Urology in July looks at the treatment of patients with a specific type of kidney cancer where the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). This is called sarcomatoid kidney cancer and patients with […]

read more

Diagnostic biomarkers for rare subtype of kidney cancer

There are more than 10 different subtypes of renal cell carcinoma (RCC), each with important genetic differences that determine how aggressive they are or their response to treatment. Clear cell RCC is the most common subtype, accounting for 75-80% of cases. A team of scientists at the University of Michigan, USA, have discovered the gene […]

read more

Predictive factors for recurrence after complete metastasectomy in metastatic kidney cancer patients

In this retrospective study, published in Science Direct this month, researchers were looking to identify the factors that would help to predict whether the cancer would come back after surgical removal of renal cell carcinoma (RCC) metastases (metastasectomy). Complete metastasectomy is expected to improve the survival of patients with metastatic RCC. However, for many patients […]

read more

Atezolizumab and bevacizumab for non-clear cell renal cell carcinoma

In this video interview from Practice Update, Dr Brad McGregor from Dana-Faber Cancer Institute in Boston, USA, talks about the results from a phase 2 trial with the combination of atezolizumab plus bevacizumab in patients with metastatic non-clear cell renal cell carcinoma (RCC). The study enrolled 60 patients, 42 of which had non-clear cell RCC […]

read more

Atezolizumab and bevacizumab in patients with advanced non-clear cell renal cell carcinoma

Dr Rana McKay from University of California in San Diego, USA and Dr Monty Pal from the City of Hope Medical Centre in California, USA share in a discussion on the study design and results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal […]

read more

Sarcomatoid RCC – molecular features and new opportunities for treatment

Sarcomatoid renal cell carcinoma (RCC) is difficult to treat and has long been associated with a poor prognosis. Also, the biology of sarcomatoid RCC has remained obscure. Scientists have tried to determine the molecular profile of sarcomatoid RCC and investigate different targeted therapies for genes such as TP53, BAP1, cell cycle, and chromatin-remodelling genes. Investigation of […]

read more

Neutrophil-lymphocyte ratio for predicting survival in sarcomatoid kidney cancer

A recent study of 230 patients with sarcomatoid renal cell carcinoma (RCC) investigated pre-surgery neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, and platelet-lymphocyte ratio as biomarkers for the prediction of survival. Neutrophil-lymphocyte ratio was assessed 1 to 8 weeks after surgery, and percentage change from pre- to post-surgery was calculated. Pre-surgery neutrophil-lymphocyte ratio was a significant predictor of […]

read more

Sunitinib and pazopanib for non-clear cell and sarcomatoid kidney cancer

Non-clear cell renal cell carcinoma (RCC) and sarcomatoid renal cell carcinoma are often treated similarly to clear cell RCC with the tyrosine kinase inhibitors, sunitinib and pazopanib. A recent study investigated the effectiveness of these two drugs for the first-line treatment of metastatic non-clear cell and sarcomatoid RCC. Of the 53 patients included in the […]

read more

ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101

Results from the JAVELIN Renal 101 study to evaluate avelumab plus axitinib in untreated sarcomatoid renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Sarcomatoid differentiation can occur in all subtypes of renal cell carcinoma (RCC) and is an aggressive form of RCC. JAVELIN […]

read more
Showing 1 to 10 of 17 results
  TOP